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Abstract
Background: Chronic Lymphocytic Leukemia (CLL) is the most frequent lymphoproliferative disorder in western
countries and is characterized by a remarkable clinical heterogeneity. During the last decade, multiple genomic
studies have identified a myriad of somatic events driving CLL proliferation and aggressivity. Nevertheless, and
despite the mounting evidence of inherited risk for CLL development, the existence of germline variants associated
with clinical outcomes has not been addressed in depth.
Methods: Exome sequencing data from control leukocytes of CLL patients involved in the International Cancer
Genome Consortium (ICGC) was used for genotyping. Cox regression was used to detect variants associated with
clinical outcomes. Gene and pathways level associations were also calculated.
Results: Single nucleotide polymorphisms in PPP4R2 and MAP3K4 were associated with earlier treatment need. A
gene-level analysis evidenced a significant association of RIPK3 with both treatment need and survival. Furthermore,
germline variability in pathways such as apoptosis, cell-cycle, pentose phosphate, GNα13 and Nitric oxide was
associated with overall survival.
Conclusion: Our results support the existence of inherited conditionants of CLL evolution and points towards
genes and pathways that may results useful as biomarkers of disease outcome. More research is needed to
validate these findings.
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Background
Chronic Lymphocytic Leukemia (CLL) is the most fre-
quent lymphoproliferative disease in western countries,
and it shows remarkable clinical heterogeneity [1]. Re-
cently, some studies demonstrated a wealth of genomic
and epigenomic differences that determine part of its
clinical aggressivity [2], such as point mutations in
NOTCH1, SF3B1, ATM, TP53 and POT1, and the ab-
sence of somatic hypermutation in the IGHV locus.
Inherited predisposition to the development of CLL
has been addressed by various genome wide association
studies (GWAS) during the last years. In this regard,
dozens of common variants at genes such as BCL2,
EOMES, CASP10 and POT1 have been associated with
significant risk of CLL development [3–5]. Similarly,
GWAS studies in other lymphoproliferative disorders
such as follicular lymphoma and diffuse large B cell
lymphoma have found evidence for the association of
germline variants with overall survival (OS) and
progression-free survival [6, 7]. Despite this evidence,
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analysis of CLL clinical evolution have been limited al-
most exclusively to acquired somatic events.
In this paper, we addressed for the first time to our
knowledge the association of common genomic variants
with time to treatment (TTT) and OS of CLL patients
participating in the Spanish ICGC cohort. Our results
suggest the existence of polymorphisms at some genes
(e.g., PPP4R2 and MAP3K4) significantly associated with
TTT. Moreover, we found significant associations with
TTT and OS both at the gene and pathway-level, which




We applied for access to the International Cancer Gen-
ome Consortium (ICGC) CLL sequencing data [8] depos-
ited in the European Genome-Phenome Database (EGA).
The Data Access Committee approved access to this
data under DACO-1040945. We downloaded exome-seq
data from control non-tumoral samples from patients
with CLL under the accession code EGAD00001001464.
Data preprocessing
Exome-seq data were previously aligned to the reference
genome (GRCh37.75) using bwa [9] as described in
Puente et al [10]. Briefly, 3 μg of genomic DNA were
used for paired-end sequencing library construction,
followed by enrichment in exomic sequences using the
SureSelect Human All Exon 50Mb v4 kit or the SureSe-
lect Human All Exon 50Mb +UTR kits (Agilent Tech-
nologies). Next, DNA was pulled down using magnetic
beads with streptavidin, followed by 18 cycles of amplifi-
cation. Sequencing was performed on an Illumina GAIIx
or on a HiSeq2000 sequencer (2x76bp). Duplicate read
removal, sorting and indexing was done using samtools
[11]. Base quality score recalibration was made with
BamUtil [12] using a logistic regression model.
Variant detection and filtering
Platypus2 [13] was run on genotyping mode. All dbSNP
variants [14] were used as input for genotyping. We
used the following specifications: “minVarFreq = 0.02”,
“minReads = 2”, “maxReads = 8000”, “assemble = 1”,
“minBaseQual = 20”, “trimSoftClipped = 1”, “minPoster-
ior = 20”, “sbThreshold = 0.01”, “badReadsWindow = 15”
and “badReadsThreshold = 15”, at least 10 reads cover-
ing a position and 2 reads covering a variant, a mini-
mum genotype quality (GQ) of 20 Phred, genotype
likelihood (GL) below − 3, maximum homopolymer run
(HP) below 11, minimum variant quality adjusted per
read depth (QD) above 2 and minimum median mini-
mum base quality for bases around variant (MMLQ)
above 10. Variants labeled by platypus as “HapScore”,
“SC”, “strandBias” and “MQ” were discarded. Heterozy-
gous loci with variant allele frequency (VAF) < 35% or >
70% were also discarded.
Sample filtering
We used principal component analysis (PCA) to detect
outliers in our study cohort. Similarly, identity-by-descent
(IBD) was used to discard all individuals with a degree of
relatedness equivalent to third degree or higher. PCAs
and IBD data were computed on a linkage disequilibrium
(LD) pruned dataset (LD upper threshold of 0.2) using the
Bioconductor [15] package SNPRelate [16]. Our final fil-
tered dataset contained 426 cases. Among these, 253 were
males and 173 were females. By IGHV status, there
were 146 unmutated cases and 273 mutated cases;
and by clinical staging, the data contained 47 mono-
clonal B-cell lymphocytosis (MBL), 332 Binet A, 37
Binet B and 8 Binet C cases. Information about clin-
ical staging and IGHV mutation status was not avail-
able for 2 and 7 cases, respectively.
Regression analysis
Cox regression and assumption of proportional hazards
was performed with the survival R package [17, 18]. Var-
iables with p-value < 0.2 in a univariate model were se-
lected as covariates for the GWAS. In the cases of TTT
these were “donor sex”, “IGHV mutation status” and
“Binet stage”; whilst in the case of overall survival we
used “IGHV mutation status”, “Binet stage” and “donor
age at diagnosis” as covariates. Three association models
were computed: an additive model, a dominant model
and a recessive model. P-values were adjusted using the
Benjamini-Hochberg (BH) method.
Due to the heterogeneity of exome-seq coverage and
quality metrics, many variables had incomplete data. We
included in the analysis variables with at least 25% call
rate, a minimum of 10 events (progression or death). A
minimum allele frequency of 1% was selected as the low-
est threshold. Furthermore, we only analyzed polymor-
phisms where Platypus called at least 10 minor alleles
(additive model) or genotypes (dominant and recessive
models).
Inflation values were estimated with the R package
QQperm [19]. Briefly, a random distribution of p-values
was created by randomly permuting phenotype variables.
Then, the association p-values are compared with the
null. This method doesn’t consider the null distribution
to be distributed uniformly.
Gene-level analysis
VEGAS2 [20] was used to calculate LD-adjusted associ-
ation p-values for TTT and OS. Briefly, VEGAS2 takes
GWAS p-values, and then uses a simulation-based
approach using information from population variant
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reference panels to adjust for LD effects. We used the
1000 Genomes phase 3 data from the iberian population
in Spain as our reference population, since all patients of
this cohort were of Spanish origin [21]. Only variants
falling within the 5′ and 3′ coordinates of RefSeq genes
were included. P-values were adjusted for multiple test-
ing using the BH method.
Pathways and gene ontology (GO) analysis
GSEA4GWAS version 1.1 [22] was used for testing sig-
nificant associations in pathways and biological process
annotations. Our input pathways were “Canonical Path-
ways” and “Gene Ontology Biological Process”. Maximum
distance was set to 20 Kb, and the major histocompati-
bility complex region was masked from the analysis.
P-values were adjusted with the BH method.
Results
Genomic polymorphisms associated with treatment-free
survival
We created three models to analyze variant association
with time to first treatment: an additive, a dominant and
a regressive model. PCA plots (Additional file 1: Figure
S1) and lambda inflation values (lambda values of 1.06,
1.03 and 1.04, Fig. 1) revealed no significant inflation or
population stratification. In the additive model we ob-
served 6 polymorphisms associated with TTT (BH ad-
justed p-value < 0.05), and other 6 showed association
with BH adjusted p-value in the range of 0.05–0.1 (Fig. 2,
Table 1, Additional file 9 Table S1). These variants were
located in MAP3K4, PEX26 (4 variants), PPP4R2 (2 vari-
ants), TTLL12/TSPO, TXNRD2, ZCCHC7, MKI67IP and
MARCH10. Notably, rs537453728 at MAP3K4 broke the
genome-wide association p-value (4.53 × 10− 8). Other
391 variants were suggestively associated with TTT (BH
adjusted p-value 0.1–0.5).
The dominant and the recessive models evidenced
very significant enrichment of variants at PPP4R2 (low-
est p-value at rs7620924: 8.07 × 10− 11). Variants at
GPR98, MAP3K4 and TTLL12 were also significantly as-
sociated with TTT (BH adjusted p-value < 0.05) (Figs. 3
and 4, Table 1, Additional file 9: Tables S2 and S3).
Some of this polymorphisms are associated with func-
tional changes in their corresponding genes. According
Fig. 1 QQplots for the TTT and OS additive, dominant and recessive models
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to dbSNP [14], rs2247870 induces a missense change in
the GPR98 gene. In a similar fashion, a search in the
HaploReg database [23] points toward functional
implications of some of these variants. For example,
rs7620924 is located in a lymphocyte-specific enhancer
region that is strongly associated with PPP4R2 expres-
sion in whole blood (p-value 2.18 × 10− 34) and in lym-
phoblastoid cells (p-value 2.36 × 10− 8). Similarly, the
polymorphisms rs361807, rs361946, rs5992169 and
rs1043278 in PEX36 are associated with PEX36 expres-
sion in lymphoblastoid cells (minimum p-value 6.66 ×
10− 10). rs9463 in TTLL12 strongly correlates with the
expression of the adjacent gene TSPO (p-value 9.81 ×
10− 198), and to a lower extent, with TTLL12 (p-value
9.57 × 10− 4) in blood cells. Other polymorphisms sug-
gestively associated with TTT such as those in TXNRD2
and ZCCHC7 are also significantly associated with the
expression of their respective genes in blood cells. On
the contrary, no functional information exists about the
intronic variant rs537453728 within the MAP3K4 gene.
Fig. 2 Manhattan plot of the additive TTT model results
Table 1 Results of the additive, dominant and recessive TTT models. Polymorphisms with a BH-adjusted P-value < 0.1 are show
rs ID P-value BH-adjusted P-value Reference Alternative Gene Symbol Hazard Ratio MAF
ADDTIVE MODEL
rs537453728 4.53E-08 5.39 E-3 CT C MAP3K4 7.08 0.01
rs361807 4.31E-07 0.01 T C PEX26 4.55 0.1
rs361946 4.31E-07 0.01 A G PEX26 4.55 0.1
rs1043278 4.31E-07 0.01 A G PEX26 4.55 0.1
rs7620924 5.08E-07 0.01 A G PPP4R2 0.24 0.49
rs5992169 9.55E-07 0.02 G A PEX26 4.45 0.11
rs9463 3.11E-06 0.05 G A TTLL12 3.18 0.42
rs55715863 3.84E-06 0.05 C A TXNRD2 5.24 0.01
rs3780333 3.84E-06 0.05 A G ZCCHC7 4.8 0.27
rs17016977 5.69E-06 0.07 A G MKI67IP 5.53 0.01
rs72842201 6.13E-06 0.07 A G MARCH.10 2.99 0.05
rs3172278 7.23E-06 0.07 T C PPP4R2 4.04 0.49
DOMINANT MODEL
rs3172278 2.40E-08 1.23E-03 T C PPP4R2 0.09 0.49
rs2247870 1.60E-07 4.10E-03 G A GPR98 0.4 0.47
rs9463 3.07E-07 5.26E-03 G A TTLL12 0.17 0.42
rs28656102 1.22E-06 0.02 T C PPP4R2 0.18 0.42
rs1045960 6.22E-06 0.05 C T PPP4R2 0.21 0.42
rs62039297 6.29E-06 0.05 G A SRL 0.2 0.26
rs9873229 9.72E-06 0.07 C T PPP4R2 0.22 0.44
RECESSIVE MODEL
rs7620924 8.07E-11 1.08E-05 A G PPP4R2 11.77 0.49
rs537453728 4.53E-08 3.04E-03 CT C MAP3K4 0.14 0.01
rs9310254 7.49E-07 0.03 T C PPP4R2 5.56 0.49
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Genomic polymorphisms associated with overall survival
We created an additive, a dominant and a recessive model
to investigate variant association with OS. No significant
inflation was observed (lambda values of 1.02, 1.01 and
1.01 for additive, dominant and recessive models, respect-
ively). No variant achieved BH-adjusted p-values below
0.05 in any model (Additional file 2: Figure S2, Additional
file 3: Figure S3 Additional file 4: Figure S4, Table 2,
Additional file 9: Tables S4-S6). Nevertheless, 20 variants
were below 0.06 in the additive models, with the top vari-
ants falling in TTC32, WDR35 and CLIP1. Notably,
rs2304588 at TTC32 achieved the lowest p-value (7.6 ×
10− 7, Bonferroni-adjusted p-value 0.067, BH-adjusted
p-value 0.056). Overall, the number of variants with BH
adjusted p-values below 0.1 was 25 in the additive model,
4 in the dominant model and 18 in the recessive model.
Gene-based association with TTT and OS
Gene-level integration of p-values for the TTT model
using VEGAS2 evidenced the association of 5 genes with
BH adjusted p-values < 0.05 and 10 genes with BH
adjusted p-values in the range of 0.05–0.1 (Table 3,
Additional file 9: Table S7). The most significant genes
were AURKAIP1, NIFK, RIPK3, SIK1 and ZCCHC7.
Similarly, we observed 12 genes associated with OS at
a BH-adjusted p-value < 0.05 (Table 2, Additional file 9:
Table S8), namely CLUAP1, TTC32, DRD3, RAD51AP2,
RIPK3, EPYC, TENM4, GTPBP1, GAMT, DCP1B,
MIR548D1 and MIR548AA1. Other 5 genes were associ-
ated with OS with BH-adjusted p-values in the range of
0.05–0.1. These genes were WDR35, BNIPL, KARS,
ACO1 and PARP6.
Pathway-level variation significantly associated with TTT
and OS
We used GSEA4GWAS to analyze associations with TTT
and OS at the pathway level. No significant enrichment
neither in “Canonical pathways” nor in “Biological
Process” terms was observed for the TTT variable. Never-
theless, a different scenario was found for the OS variable.
Significant “Canonical pathways” annotations (BH-ad-
justed p-values < 0.05) were “Pentose Phosphate pathway”,
“Gluconeogenesis”, “Glycolysis”, “GNα13 pathway”, “Nitric
Oxide pathway”, “Apoptosis”, “Glycolysis and Gluconeo-
genesis”, “Tumor Necrosis Factor pathway”, “Ovarian Infer-
tility genes”, “Bile Acid Biosynthesis”, “Keratinocyte
pathway” and “Glycine Serine and Threonine pathway”
(Table 4, Additional file 5: Figure S5 and Additional file 6:
Figure S6). Other pathways had evidence of suggestive as-
sociation (BH-adjusted p-value < 0.25), such as “Notch Sig-
nalling pathway”, “EGF pathway”, “JNK MAPK pathway”
and “PDGF pathway” among others. Among “GO Bio-
logical Processes” terms, the following were associated
with OS with a BH-adjusted p-value < 0.05: “Induction of
Apoptosis by Extracellular Signals”, “Mitosis”, “M phase”,
“M phase of mitotic cell cycle” and “Negative regulation of
Developmental Process”. Terms with BH-adjusted p-value
< 0.25 were “Anti Apoptosis”, “Chromosome Segregation”,
“Vasculature Development” and “Negative Regulation of
Apoptosis”, among others (Table 4, Additional file 7:
Figure S7 and Additional file 8: Figure S8).
Discussion
In this work we present evidence that suggest the exist-
ence of germline variation modulating CLL’s clinical ag-
gressivity. The most remarkable finding was the strong
and recessive association of rs7620924 near PPP4R2 with
short time to treatment. The implication of PPP4R2 in
the regulation of cell survival and DNA repair in
hematopoietic and leukemia cells has been recently re-
ported [24]. Indeed, different studies have identified
Fig. 4 Manhattan plot of the recessive TTT model result
Fig. 3 Manhattan plot of the dominant TTT model results
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Table 2 Results of the additive, dominant and recessive OS models. Polymorphisms with a BH-adjusted P-value < 0.1 are show
rs ID P-value BH-adjusted P-value Reference Alternative Symbol Hazard Ratio MAF
ADDITIVE
rs2304588 7.36E-07 0.06 A G TTC32 6.59 0.08
rs2293671 1.43E-06 0.06 T C WDR35 4.97 0.08
rs139689179 2.17E-06 0.06 G C CLIP1 33.51 0.02
rs149301745 3.45E-06 0.06 ACTT A SPATA5L1 6.04 0.04
rs56127964 3.88E-06 0.06 A G ACO1 7.51 0.02
rs1800502 4.65E-06 0.06 A G CFTR 6.23 0.024
rs1060742 4.88E-06 0.06 T C WDR35 4.05 0.08
rs72860063 4.98E-06 0.06 A G KIF6 11.19 0.02
rs7563410 6.46E-06 0.06 C A TTC32 3.97 0.08
rs28502265 6.48E-06 0.06 T G WDR35 3.98 0.08
rs769479742 7.23E-06 0.06 T G PDE1C 7.39 0.03
rs76774695 7.96E-06 0.06 C T PARP6 10.54 0.01
rs148915854 8.41E-06 0.06 T TA FAM184B 5.19 0.07
rs114314465 9.74E-06 0.06 A C SLC4A5 10.69 0.02
rs3732783 9.77E-06 0.06 T C DRD3 13.34 0.09
rs117149407 9.79E-06 0.06 G A EYA1 14.24 0.03
rs12194408 1.14E-05 0.06 C G PPIL1 7.15 0.02
rs1790557 1.16E-05 0.06 C T TENM4 7.98 0.25
rs35034822 1.27E-05 0.06 T G PROM2 14.77 0.02
rs147203128 1.29E-05 0.06 G A CYTH2 12.94 0.02
chr2:95944632 1.42E-05 0.06 T G PROM2 14.47 0.02
rs200619224 1.49E-05 0.06 A C CDC23 6.15 0.02
rs75827446 1.57E-05 0.06 T C TNL2 43.14 0.02
rs1053361 1.68E-05 0.06 G C RHCE 11.75 0.02
rs7270676 2.44E-05 0.09 T C SEMG1 6.84 0.04
DOMINANT
rs7512589 3.71E-06 0.07 G A CELA2A 0.21 0.29
rs3737697 3.93E-06 0.07 C T CELA2A 0.21 0.29
rs62039297 9.09E-06 0.1 G A SRL 0.06 0.26
rs10783474 1.08E-05 0.1 G A SCN8A 0.11 0.16
RECESSIVE
rs2304588 7.36E-07 0.05 A G TTC32 0.15 0.08
rs2293671 1.12E-06 0.05 T C WDR35 0.18 0.08
rs139689179 2.17E-06 0.06 G C CLIP1 0.03 0.02
rs149301745 3.45E-06 0.06 ACTT A SPATA5L1 0.17 0.04
rs1060742 4.18E-06 0.06 T C WDR35 0.23 0.08
rs72860063 4.98E-06 0.06 A G KIF6 0.09 0.02
rs7563410 5.41E-06 0.06 C A TTC32 0.24 0.08
rs28502265 5.59E-06 0.06 T G WDR35 0.24 0.08
rs769479742 7.23E-06 0.07 T G PDE1C 0.14 0.03
rs76774695 7.96E-06 0.07 C T PARP6 0.09 0.01
rs114314465 9.74E-06 0.08 A C SLC4A5 0.09 0.02
rs117149407 9.79E-06 0.08 G A EYA1 0.07 0.03
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Table 2 Results of the additive, dominant and recessive OS models. Polymorphisms with a BH-adjusted P-value < 0.1 are show
(Continued)
rs ID P-value BH-adjusted P-value Reference Alternative Symbol Hazard Ratio MAF
rs12194408 1.14E-05 0.08 C G PPIL1 0.14 0.02
rs35034822 1.27E-05 0.08 T G PROM2 0.07 0.02
chr2:95944632 1.42E-05 0.08 T G PROM2 0.07 0.02
rs200619224 1.49E-05 0.08 A C CDC23 0.16 0.02
rs75827446 1.57E-05 0.08 T C TLN2 0.02 0.02
rs1053361 1.68E-05 0.09 G C RHCE 0.09 0.02
Table 3 VEGAS2 gene-level analysis of the additive TTT and OS models. Genes with a BH-adjusted P-value < 0.1 are shown
Gene nSNPs nSims Test P value TopSNP TopSNP.p value BH-ajdusted p-value
VEGAS2 Analysis of TTT
AURKAIP1 2 1.00E+06 26.72 1.00E-06 rs2765035 2.28E-04 6.90E-03
NIFK 4 1.00E+06 36.22 1.00E-06 rs17016977 5.69E-06 6.90E-03
RIPK3 7 1.00E+06 22.32 2.00E-06 rs28379107 0.02 9.20E-03
SIK1 3 1.00E+06 31.07 9.00E-06 rs3746951 2.32E-05 0.03
ZCCHC7 2 1.00E+06 23.2 1.10E-05 rs3780333 3.84E-06 0.03
ABCA7 18 1.00E+06 88.04 2.30E-05 rs3752230 3.22E-04 0.05
PEX26 7 1.00E+06 83.49 2.70E-05 rs361807 4.31E-07 0.05
AARS 3 1.00E+06 17.21 4.10E-05 rs2070203 2.34E-03 0.06
NIFK-AS1 3 1.00E+06 24.72 4.50E-05 rs17016977 5.69E-06 0.06
TSPO 2 1.00E+06 24.36 4.60E-05 rs6971 7.18E-05 0.06
MARCH.10 2 1.00E+06 20.45 4.80E-05 rs72842201 6.13E-06 0.06
LOC574538 3 1.00E+06 24.15 7.20E-05 rs56204927 1.94E-04 0.08
SEC24D 10 1.00E+06 44.69 7.60E-05 rs115446044 1.09E-03 0.08
TTLL12 9 1.00E+06 54.06 9.90E-05 rs9463 3.11E-06 0.1
GALNT11 4 1.00E+06 15.18 1.07E-04 rs146169444 0.01 0.1
VEGAS2 Analysis of OS
CLUAP1 7 1.00E+06 57.76 1.00E-06 rs78851263 3.27E-04 6.17E-03
TTC32 5 1.00E+06 66.51 1.00E-06 rs2304588 7.36E-07 6.17E-03
DRD3 2 1.00E+06 21.54 4.00E-06 rs3732783 9.77E-06 0.02
RAD51AP2 7 1.00E+06 22.31 6.00E-06 rs62130401 0.02 0.02
RIPK3 8 1.00E+06 18.64 1.30E-05 rs3212251 0.01 0.03
EPYC 2 1.00E+06 17.78 2.00E-05 rs76171854 3.25E-04 0.03
TENM4 13 1.00E+06 75.05 2.10E-05 rs1790557 1.16E-05 0.03
GTPBP1 6 1.00E+06 17.81 2.30E-05 rs16999297 6.42E-03 0.03
GAMT 2 1.00E+06 17.56 2.80E-05 rs266809 8.65E-05 0.03
DCP1B 16 1.00E+06 61.9 3.00E-05 rs150660202 7.13E-03 0.03
MIR548D1 3 1.00E+06 17.35 3.30E-05 rs12141159 4.48E-04 0.03
MIR548AA1 3 1.00E+06 17.35 3.40E-05 rs12141159 4.48E-04 0.03
WDR35 14 1.00E+06 89.29 5.90E-05 rs2293671 1.43E-06 0.06
BNIPL 6 1.00E+06 23.11 7.40E-05 rs955955 2.91E-03 0.06
KARS 3 1.00E+06 15.43 1.05E-04 rs148298278 1.28E-04 0.09
ACO1 13 1.00E+06 57.84 1.26E-04 rs56127964 3.88E-06 0.1
PARP6 3 1.00E+06 21.16 1.33E-04 rs76774695 7.96E-06 0.1
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Table 4 GSEA4GWAS analysis of the additive OS model. Gene Ontology Biological Process and Canonical Pathways terms with a BH-
adjusted P-value < 0.25 are shown
Pathway/Gene set name P-value FDR Significant genes/Selected genes/All genes
GSEA4GWAS Biological Process results for the Additive OS model
INDUCTION OF APOPTOSIS BY EXTRACELLULAR SIGNALS < 0.001 0.01 9/21/27
MITOSIS < 0.001 0.02 23/68/82
M PHASE < 0.001 0.02 31/96/114
M PHASE OF MITOTIC CELL CYCLE < 0.001 0.04 23/70/85
NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 0.001 0.05 36/148/197
ANTI APOPTOSIS < 0.001 0.05 20/83/118
CHROMOSOME SEGREGATION 0.003 0.1 10/29/32
CELL CYCLE PHASE 0.001 0.13 38/144/170
CELL CYCLE PROCESS < 0.001 0.19 42/160/193
REGULATION OF MITOSIS 0.004 0.19 11/36/41
VASCULATURE DEVELOPMENT 0.007 0.24 14/43/55
SKELETAL DEVELOPMENT 0.011 0.25 23/80/103
GAMETE GENERATION 0.011 0.25 18/76/114
NEGATIVE REGULATION OF APOPTOSIS 0.008 0.25 21/112/150
NEGATIVE REGULATION OF PROGRAMMED CELL DEATH 0.008 0.25 21/112/151
GSEA4GWAS Cannonical Pathways results for the Additive OS model
PENTOSE PHOSPHATE PATHWAY < 0.001 1.67E-03 8/19/25
GLUCONEOGENESIS < 0.001 2.00E-03 18/47/53
GLYCOLYSIS < 0.001 2.00E-03 18/47/53
HSA00030 PENTOSE PHOSPHATE PATHWAY < 0.001 0.01 8/21/26
ST GA13 PATHWAY < 0.001 0.02 11/29/37
NO1PATHWAY < 0.001 0.03 11/26/31
HSA04210 APOPTOSIS 0.001 0.03 19/68/84
HSA00010 GLYCOLYSIS AND GLUCONEOGENESIS 0.001 0.03 17/58/64
ST TUMOR NECROSIS FACTOR PATHWAY < 0.001 0.04 7/20/29
OVARIAN INFERTILITY GENES 0.001 0.04 8/21/25
BILE ACID BIOSYNTHESIS 0.002 0.04 9/23/27
KERATINOCYTEPATHWAY 0.001 0.04 12/37/46
GLYCINE SERINE AND THREONINE METABOLISM 0.006 0.05 9/28/37
BREAST CANCER ESTROGEN SIGNALING 0.001 0.06 21/78/101
GLYCEROLIPID METABOLISM 0.008 0.09 13/36/45
NOS1PATHWAY 0.01 0.1 7/20/22
HSA00120 BILE ACID BIOSYNTHESIS 0.003 0.11 11/36/38
HSA04330 NOTCH SIGNALING PATHWAY 0.011 0.11 10/35/47
FRUCTOSE AND MANNOSE METABOLISM 0.01 0.11 7/21/25
EGFPATHWAY 0.009 0.11 8/24/27
HSA05218 MELANOMA 0.01 0.11 13/58/71
ST JNK MAPK PATHWAY 0.011 0.12 10/33/40
PDGFPATHWAY 0.011 0.12 8/24/27
TYROSINE METABOLISM 0.015 0.12 8/24/32
HSA05223 NON SMALL CELL LUNG CANCER 0.009 0.12 13/47/54
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PPP4R2 as a modulator of protein phosphatase 4 (PPP4),
which regulates DNA repair through non-homologous
end joining [25]. Concordantly, the ablation of PPP4 ac-
tivity in mice increases genomic instability and aborgates
class switch recombination in B cells, leading to an ab-
normal immune response [26]; and its function also
seems to be essential in V(D) J recombination during
normal B cell maturation [27]. Other polymorphisms as-
sociated with time to first treatment were located in
MAP3K4, PEX26 and TTLL12. MAP3K4 participates in
the TRAIL/MAP3K4/p38/HSP27/Akt pathway, thereby
modulating processes such as autophagy and cell migra-
tion. Indeed, MAP3K4 is affected by recurrent
loss-of-function mutations in different types of cancers
[28–32]. Conversely, less is known about the
peroxisome-related gene PEX26 [33]; the G-protein
GPR98; and TTLL12, which participates in chromosome
stability and mitosis-related processes [34]. On the con-
trary, although we did not find any variant significantly
associated with overall survival, we devised some vari-
ants with suggestive associations. The two most signifi-
cant ones were in the TTC32/WDR35 and CLIP1 loci,
the last of which is overexpressed in Reed-Sternberg
cells of Hodgkin lymphoma [35, 36].
In a similar fashion, we detected variation on different
genes associated with CLL evolution. The most relevant
was the association of RIP3K with both time to treat-
ment and overall survival. RIP3K encodes a protein that
regulates necroptosis, a form of regulated cell death
characterized by cell membrane permeabilization [37].
Other relevant genes associated with rapid progression
were the pro-proliferative gene NIFK [38], the tumor
suppressor SIK1 [39, 40] and ZCCHC7, which is
encoded near the B-cell specific PAX5 super-enhancer
locus [41, 42]. On the other hand, various genes were as-
sociated with overall survival, such as CLUAP1, which
participates in tumor growth and cytoskeleton regulation
[43–45]; and the enzyme GAMT, which converts
S-adenosylmethionine to creatine in order to foster high
energy demands [46]. Moreover, the BCL-2 interacting
gene BNIPL [47, 48] was suggestively associated with
survival and deserves further characterization. In the
same direction, the most remarkable pathway-level asso-
ciation with survival was that of the pentose phosphate
metabolic pathway, which fuels cells with metabolites for
nucleotide and lipid biosynthesis, and provides reducing
power to promote cell survival under stressful condi-
tions [49]. Other pathways such as GNα13 and Nitric
Oxide were also significant. Concordantly, recurrent in-
activating mutations in the G-protein superfamily gene
GNA13 have been described in B cell lymphomas [50–
53], and the contribution of nitric oxide to apoptosis
resistance in CLL cells has been addressed by various
studies [54, 55].
The main limitation of this study is the lack of an in-
dependent cohort for validation of these findings. Fur-
thermore, although inflation values were low, we assume
that treatment heterogeneity could have an impact on
overall survival associations. Nevertheless, the global re-
sults are not only statistical significant but also biologic-
ally plausible. Thus, we believe that this report will
motivate further studies in order to confirm the effect of
these variants and to determine their mechanisms of
action in lymphoproliferative disorders.
Table 4 GSEA4GWAS analysis of the additive OS model. Gene Ontology Biological Process and Canonical Pathways terms with a BH-
adjusted P-value < 0.25 are shown (Continued)
Pathway/Gene set name P-value FDR Significant genes/Selected genes/All genes
HSA00760 NICOTINATE AND NICOTINAMIDE METABOLISM 0.019 0.14 7/20/24
HSA00051 FRUCTOSE AND MANNOSE METABOLISM 0.013 0.14 10/35/42
BUTANOATE METABOLISM 0.017 0.14 7/26/29
HSA00260 GLYCINE SERINE AND THREONINE METABOLISM 0.018 0.15 8/36/45
HSA00561 GLYCEROLIPID METABOLISM 0.022 0.19 15/49/58
STRIATED MUSCLE CONTRACTION 0.023 0.2 11/31/39
PPARAPATHWAY 0.023 0.2 11/43/57
HSA04510 FOCAL ADHESION 0.015 0.2 53/171/200
G1PATHWAY 0.04 0.21 4/22/28
HSA05222 SMALL CELL LUNG CANCER 0.024 0.21 22/78/87
HSA05010 ALZHEIMERS DISEASE 0.029 0.21 7/23/28
HIVNEFPATHWAY 0.029 0.22 13/46/58
HSA04662 B CELL RECEPTOR SIGNALING PATHWAY 0.041 0.23 15/57/64
HSA05214 GLIOMA 0.035 0.24 14/56/64
NFATPATHWAY 0.039 0.24 11/46/53
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Conclusions
Our results point towards the existence of germline vari-
ability as a determinant of CLL clinical aggressivity. Fu-
ture studies to validate and characterize the activity of
these variants in CLL are needed.
Additional files
Additional file 1: Figure S1. Principal component plots for the subjects
included in the final analysis. (JPG 154 kb)
Additional file 2: Figure S2. Manhattan plot of the additive OS model
results. (JPG 199 kb)
Additional file 3: Figure S3. Manhattan plot of the dominant OS
model results. (JPG 222 kb)
Additional file 4: Figure S4. Manhattan plot of the recessive TTT model
results. (JPG 193 kb)
Additional file 5: Figure S5. Manhattan plot for the Pentose Phosphate
pathway. (JPG 56 kb)
Additional file 6: Figure S6. Manhattan plot for the GNα13 pathway.
(JPG 54 kb)
Additional file 7: Figure S7. Manhattan plot for the “Induction of
apoptosis by extracellular signal” biological process. (JPG 59 kb)
Additional file 8: Figure S8. Manhattan plot for the “Mitosis” biological
process. (JPG 54 kb)
Additional file 9: Table S1. GWAS results of the additive Cox regression
model for TTT. Polymorphisms with a BH-adjusted P-value < 0.5 are
shown. Table S2. GWAS results of the dominant Cox regression model
for TTT. Polymorphisms with a BH-adjusted P-value < 0.5 are shown.
Table S3. GWAS results of the recessive Cox regression model for TTT.
Polymorphisms with a BH-adjusted P-value < 0.5 are shown. Table S4.
GWAS results of the additive Cox regression model for OS. Polymorphisms
with a BH-adjusted P-value < 0.5 are shown. Table S5. GWAS results
of the dominant Cox regression model for OS. Polymorphisms with a
BH-adjusted P-value < 0.5 are shown. Table S6. GWAS results of the
recessive Cox regression model for OS. Polymorphisms with a BH-
adjusted P-value < 0.5 are shown. Table S7. VEGAS2 gene-level results
for association with TTT. Table S8. VEGAS2 gene-level results for
association with OS. (XLSX 3081 kb)
Abbreviations
BH: Benjamini-Hochberg; CLL: Chronic Lymphocytic Leukemia:;
EGA: European Genome-Phenome Database; IBD: Identity By Descent;
ICGC: International Cancer Genome Consortium; LD: Linkage Disequilibrium;
MBL: Monoclonal B cell lymphocytosis; OS: Overall Survival:; PCA: Principal
Component Analysis; TTT: Time to Treatment; VAF: Variant allele frequency
Acknowledgements
We would like to thank the Supercomputing Center of Galicia (CESGA) for
providing all the informatics resources needed for performing this research.
We would also like to thank the International Cancer Genome Consortium
and the European Genome Archive for providing and facilitating data access.
The content of this paper is part of the doctoral thesis of Adrián Mosquera
Orgueira to obtain a PhD at the Department of Medicine, University of
Santiago de Compostela.
Funding
This research had no funding support.
Availability of data and materials
The data that support the findings of this study are available from the ICGC
but restrictions apply to the availability of these data, which were used
under license for the current study, and so are not publicly available. Data
are however available from the authors upon reasonable request and with
permission of the ICGC.
Authors’ contributions
AMO, BAR and JLBL designed the study and wrote the manuscript; AMO
performed the analysis; AMO, BAR, CAT, EMGS, ACA interpreted the results;
JADA, NAV, NDV and MMPE were involved in manuscript drafting and in
critical revision for important intellectual content. All authors read and
approved the final manuscript.





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Clinical University Hospital of Santiago de Compostela, Service of
Hematology and Hemotherapy, 1st floor, Avenida da Choupana s/n, Santiago
de Compostela 15706, Spain. 2Division of Hematology, SERGAS, Complexo
Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago,
Spain. 3University of Santiago de Compostela, Santiago, Spain. 4Fundación
Pública de Medicina Xenómica, A Coruña, Spain.
Received: 16 September 2018 Accepted: 23 April 2019
References
1. Döhner H, et al. Genomic aberrations and survival in chronic lymphocytic
leukemia. N Engl J Med. 2000;343(26):1910–6.
2. Nadeu F, et al. Clinical impact of the subclonal architecture and mutational
complexity in chronic lymphocytic leukemia. Leukemia. 2018;32(3):645–53.
https://doi.org/10.1038/leu.2017.291 Epub 2017 Sep 19.
3. Speedy HE, Di Bernardo MC, Sava GP, et al. A genome-wide association
study identifies multiple susceptibility loci for chronic lymphocytic
leukemia. Nat Genet. 2014;46(1):56–60. https://doi.org/10.1038/ng.2843
Epub 2013 Dec 1.
4. Berndt SI, Skibola CF, Joseph V, et al. Genome-wide association study
identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet.
2013;45(8):868–76. https://doi.org/10.1038/ng.2652 Epub 2013 Jun 16.
5. Berndt SI, Camp NJ, Skibola CF, et al. Meta-analysis of genome-wide
association studies discovers multiple loci for chronic lymphocytic leukemia.
Meta-analysis of genome-wide association studies discovers multiple loci for
chronic lymphocytic leukemia. Nat Commun. 2016;7:10933. https://doi.org/
10.1038/ncomms10933.
6. Baecklund F, Foo JN, Bracci P, et al. A comprehensive evaluation of the role
of genetic variation in follicular lymphoma survival. BMC Med Genet. 2014;
15:113. https://doi.org/10.1186/s12881-014-0113-6.
7. Ghesquieres H, Slager SL, Jardin F, et al. Genome-wide association study of
event-free survival in diffuse large B-cell lymphoma treated with
Immunochemotherapy. J Clin Oncol. 2015;33(33):3930–7. https://doi.org/10.
1200/JCO.2014.60.2573 Epub 2015 Oct 12.
8. Ramsay AJ, et al. Next-generation sequencing reveals the secrets of the
chronic lymphocytic leukemia genome. Clin Transl Oncol. 2013;15(1):3–8.
https://doi.org/10.1007/s12094-012-0922-z Epub 2012 Aug 22.
9. Li H, et al. Fast and accurate short read alignment with burrows-wheeler
transform. Bioinformatics. 2009;25(14):1754–60. https://doi.org/10.1093/
bioinformatics/btp324 Epub 2009 May 18.
10. Puente XS, et al. Non-coding recurrent mutations in chronic lymphocytic
leukaemia. Nature. 2015;526(7574):519–24. https://doi.org/10.1038/
nature14666 Epub 2015 Jul 22.
11. Li H, et al. The sequence alignment/map format and SAMtools.
Bioinformatics. 2009;25(16):2078–9. https://doi.org/10.1093/bioinformatics/
btp352 Epub 2009 Jun 8.
12. Breese MR, Liu Y. NGSUtils: a software suite for analyzing and manipulating
next-generation sequencing datasets. Bioinformatics. 2013;29(4):494–6 Epub
2013/01/15. pmid:23314324; PubMed Central PMCID: PMC3570212.
Mosquera Orgueira et al. BMC Cancer          (2019) 19:515 Page 10 of 11
13. Rimmer A, et al. Integrating mapping-, assembly- and haplotype-based
approaches for calling variants in clinical sequencing applications. Nat
Genet. 2014;46(8):912–8. https://doi.org/10.1038/ng.3036 Epub 2014 Jul 13.
14. Database of single nucleotide polymorphisms (dbSNP). Bethesda (MD):
National Center for biotechnology information, National Library of medicine.
(dbSNP build ID: 150). Available from: http://www.ncbi.nlm.nih.gov/SNP/
15. Huber W, Carey VJ, Gentleman R, et al. Orchestrating high-throughput
genomic analysis with Bioconductor. Nat Methods. 2015;12(2):115–21.
https://doi.org/10.1038/nmeth.3252.
16. Zheng X, Levine D, Shen J, Gogarten S, Laurie C, Weir B. A high-
performance computing toolset for relatedness and principal component
analysis of SNP data. Bioinformatics. 2012;28(24):3326–8. https://doi.org/10.
1093/bioinformatics/bts606.
17. Therneau T (2015). A package for survival analysis in S. version 2.38, https://
CRAN.R-project.org/package=survival.
18. Therneau TM, Grambsch PM. Modeling survival data: extending the cox
model. New York: Springer; 2000. ISBN 0-387-98784-3
19. Slave Petrovski, Quanli Wang. QQperm: permutation based QQ plot and
inflation factor estimation. 2016. R package ersion 1.0.1. https://cran.r-
project.org/web/packages/QQperm/index.html.
20. Mishra A, Macgregor S. VEGAS2: software for more flexible gene-based
testing. Twin Res Hum Genet. 2015;18(1):86–91. https://doi.org/10.1017/thg.
2014.79 Epub 2014 Dec 18.
21. Castaño-Vinyals G, Aragonés N, Pérez-Gómez B, et al. Population-based
multicase-control study in common tumors in Spain (MCC-Spain): rationale
and study design. Gac Sanit. 2015;29(4):308–15. https://doi.org/10.1016/j.
gaceta.2014.12.003 Epub 2015 Jan 19.
22. Zhang K, Cui S, Chang S, Zhang L, Wang J. i-GSEA4GWAS: a web server for
identification of pathways/gene sets associated with traits by applying an
improved gene set enrichment analysis to genome-wide association study.
Nucleic Acids Res. 2010;38(Web Server issue):W90–5. https://doi.org/10.1093/
nar/gkq324 Epub 2010 Apr 30.
23. Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal
variants, cell types, regulators and target genes for human complex traits
and disease. Nucleic Acids Res. 2016;44(D1):D877–81. https://doi.org/10.
1093/nar/gkv1340 Epub 2015 Dec 10. PubMed PMID: 26657631; PubMed
Central PMCID: PMC4702929.
24. Herzig JK, Bullinger L, Tasdogan A, et al. Protein phosphatase 4 regulatory
subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and
required for efficient DNA double strand break repair. Oncotarget. 2017;8(56):
95038–53. https://doi.org/10.18632/oncotarget21119 eCollection 2017 Nov 10.
25. Liu J, Xu L, Zhong J, et al. Protein phosphatase PP4 is involved in NHEJ-
mediated repair of DNA double-strand breaks. Cell Cycle. 2012;11(14):2643–
9. https://doi.org/10.4161/cc.20957 Epub 2012 Jul 15.
26. Chen MY, Chen YP, Wu MS, et al. PP4 is essential for germinal center
formation and class switch recombination in mice. PLoS One. 2014;9(9):
e107505. https://doi.org/10.1371/journal.pone.0107505 eCollection 2014.
27. Su YW, Chen YP, Chen MY, et al. The serine/threonine phosphatase PP4 is
required for pro-B cell development through its promotion of
immunoglobulin VDJ recombination. PLoS One. 2013;8(7):e68804. https://
doi.org/10.1371/journal.pone.0068804 Print 2013.
28. Kanchi KL, Johnson KJ, Lu C, et al. Integrated analysis of germline and
somatic variants in ovarian cancer. Nat Commun. 2014;5:3156. https://doi.
org/10.1038/ncomms4156.
29. Yang LX, Gao Q, Shi JY, et al. Mitogen-activated protein kinase kinase kinase
4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth
and epithelial-mesenchymal transition. Hepatology. 2015;62(6):1804–16.
https://doi.org/10.1002/hep.28149 Epub 2015 Oct 17.
30. Kim J, Kang D, Sun BK, et al. TRAIL/MEKK4/p38/HSP27/Akt survival network
is biphasically modulated by the Src/CIN85/c-Cbl complex. Cell Signal. 2013;
25(1):372–9. https://doi.org/10.1016/j.cellsig.2012.10.010 Epub 2012 Oct 23.
31. Sollome JJ, Thavathiru E, Camenisch TD, Vaillancourt RR. HER2/HER3
regulates extracellular acidification and cell migration through MTK1
(MEKK4). Cell Signal. 2014;26(1):70–82. https://doi.org/10.1016/j.cellsig.2013.
08.043 Epub 2013 Sep 12.
32. Keil E, Höcker R, Schuster M, et al. Phosphorylation of Atg5 by the Gadd45β-
MEKK4-p38 pathway inhibits autophagy. Cell Death Differ. 2013;20(2):321–
32. https://doi.org/10.1038/cdd.2012.129 Epub 2012 Oct 12.
33. Weller S, Cajigas I, Morrell J, et al. Alternative splicing suggests extended
function of PEX26 in peroxisome biogenesis. Am J Hum Genet. 2005;76(6):
987–1007 Epub 2005 Apr 27.
34. Brants J, Semenchenko K, Wasylyk C, et al. Tubulin tyrosine ligase like 12, a
TTLL family member with SET- and TTL-like domains and roles in histone
and tubulin modifications and mitosis. PLoS One. 2012;7(12):e51258. https://
doi.org/10.1371/journal.pone.0051258. Epub 2012 Dec 12.
35. Perez F, Diamantopoulos GS, Stalder R, Kreis TE. CLIP-170 highlights
growing microtubule ends in vivo. Cell. 1999;96(4):517–27.
36. Sahin U, Neumann F, Tureci O, et al. Hodgkin and reed-Sternberg cell-
associated autoantigen CLIP-170/restin is a marker for dendritic cells and is
involved in the trafficking of macropinosomes to the cytoskeleton,
supporting a function-based concept of Hodgkin and reed-Sternberg cells.
Blood. 2002;100(12):4139–45.
37. Krysko O, Aaes TL, Kagan VE, et al. Necroptotic cell death in anti-cancer
therapy. Immunol Rev. 2017;280(1):207–19. https://doi.org/10.1111/imr.12583.
38. Lin TC, Su CY, Wu PY, et al. The nucleolar protein NIFK promotes cancer
progression via CK1α/β-catenin in metastasis and Ki-67-dependent cell
proliferation. Elife. 2016;17:5. https://doi.org/10.7554/eLife.11288.
39. Selvik LK, Rao S, Steigedal TS, et al. Salt-inducible kinase 1 (SIK1) is induced
by gastrin and inhibits migration of gastric adenocarcinoma cells. PLoS One.
2014;9(11):e112485. https://doi.org/10.1371/journal.pone.0112485
eCollection 2014.
40. Hong B, Zhang J, Yang W. Activation of the LKB1-SIK1 signaling pathway
inhibits the TGF-β-mediated epithelial-mesenchymal transition and
apoptosis resistance of ovarian carcinoma cells. Mol Med Rep. 2018;17(2):
2837–44. https://doi.org/10.3892/mmr.2017.8229 Epub 2017 Dec 8.
41. Núñez-Enríquez JC, Bárcenas-López DA, Hidalgo-Miranda A, et al. Gene
expression profiling of acute lymphoblastic leukemia in children with very
early relapse. Arch Med Res. 2016;47(8):644–55. https://doi.org/10.1016/j.
arcmed.2016.12.005.
42. Bertrand P, Bastard C, Maingonnat C, et al. Mapping of MYC breakpoints in
8q24 rearrangements involving non-immunoglobulin partners in B-cell
lymphomas. Leukemia. 2007;21(3):515–23 Epub 2007 Jan 18.
43. Beyer T, Bolz S, Junger K, et al. CRISPR/Cas9-mediated genomic editing
of Cluap1/IFT38 reveals a new role in actin arrangement. Mol Cell
Proteomics. 2018;17(7):1285–94. https://doi.org/10.1074/mcp.RA117.
000487 Epub 2018 Apr 3.
44. Ishikura H, Ikeda H, Abe H, et al. Identification of CLUAP1 as a human
osteosarcoma tumor-associated antigen recognized by the humoral
immune system. Int J Oncol. 2007;30(2):461–7.
45. Takahashi M, Lin YM, Nakamura Y. Isolation and characterization of a novel
gene CLUAP1 whose expression is frequently upregulated in colon cancer.
Oncogene. 2004;23(57):9289–94.
46. Yan YB. Creatine kinase in cell cycle regulation and cancer. Amino Acids.
2016;48(8):1775–84. https://doi.org/10.1007/s00726-016-2217-0 Epub 2016
Mar 28.
47. Qin W, Hu J, Guo M, et al. BNIPL-2, a novel homologue of BNIP-2, interacts
with Bcl-2 and Cdc42GAP in apoptosis. Biochem Biophys Res Commun.
2003;308(2):379–85.
48. Xie L, Qin W, Li J, et al. BNIPL-2 promotes the invasion and metastasis of
human hepatocellular carcinoma cells. Oncol Rep. 2007;17(3):605–10.
49. Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends
Biochem Sci. 2014;39(8):347–54. https://doi.org/10.1016/j.tibs.2014.06.005
Epub 2014 Jul 15.
50. Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt
lymphoma. Nat Genet. 2012;44(12):1321–5. https://doi.org/10.1038/ng.2468
Epub 2012 Nov 11.
51. Muppidi JR, Schmitz R, Green JA, et al. Loss of signalling via Gα13 in
germinal Centre B-cell-derived lymphoma. Nature. 2014;516(7530):254–8.
https://doi.org/10.1038/nature13765 Epub 2014 Sep 28.
52. Healy JA, Nugent A, Rempel RE, et al. GNA13 loss in germinal center B cells leads
to impaired apoptosis and promotes lymphoma in vivo. Blood. 2016;127(22):
2723–31. https://doi.org/10.1182/blood-2015-07-659938 Epub 2016 Mar 17.
53. Morin RD, Mungall K, Pleasance E, et al. Mutational and structural analysis of
diffuse large B-cell lymphoma using whole-genome sequencing. Blood.
2013;122(7):1256–65. https://doi.org/10.1182/blood-2013-02-483727 Epub
2013 May 22.
54. Kolb JP, Roman V, Mentz F, et al. Contribution of nitric oxide to the
apoptotic process in human B cell chronic lymphocytic leukaemia. Leuk
Lymphoma. 2001;40(3–4):243–57.
55. Zhao H, Dugas N, Mathiot C, et al. B-cell chronic lymphocytic leukemia cells
express a functional inducible nitric oxide synthase displaying anti-
apoptotic activity. Blood. 1998;92(3):1031–43.
Mosquera Orgueira et al. BMC Cancer          (2019) 19:515 Page 11 of 11
